Overview

The Health Service Medical Supplies (Costs) Bill aims to improve the National Health Service's (NHS) purchasing of medicines and medical supplies, ensuring best value while considering the UK life sciences sector and patient access to new treatments.

Description

The bill focuses on amending existing legislation to improve NHS purchasing practices for medicines and medical supplies. The initial Lords amendment proposed that the government has a “duty to have regard” to the life sciences sector and patient access to new treatments when securing best value. The Commons disagreed, stating this was inappropriate regarding price controls. Subsequently, a revised Lords amendment, and further Commons amendments resulted in a compromise. The final version mandates that the government “take account” of:

• Promoting a thriving UK life sciences sector.
• Ensuring swift patient access to new, clinically effective, and cost-effective medicines and treatments approved by NICE.

Furthermore, the Secretary of State must consult on the exercise of any relevant powers, considering economic consequences for the life sciences industry, the wider UK economy, and impacts on patients.

Government Spending

The bill doesn't directly allocate new funds. Its impact on government spending is indirect, potentially influencing the cost of medicines and medical supplies procured by the NHS. Precise financial implications are not specified in the provided text.

Groups Affected

• NHS: The bill directly impacts NHS procurement processes and potentially the cost of medications.
• Life Sciences Sector: The bill aims to support this sector by considering its economic impact on purchasing decisions.
• Patients: The bill seeks to ensure access to new treatments, affecting patient care and outcomes.
• Pharmaceutical Companies: The bill’s impact on drug pricing and procurement strategies will affect their profitability and operations in the UK.

Powered by nyModel